SUBSTITUTED 2-PHENYLBENZOTHIAZOLES
2661
REFERENCES
1. Weekes, A. A.; Westwell, A. D. 2-Arylbenzothiazole as a privileged scaffold in drug dis-
covery. Curr. Med. Chem. 2009, 16, 2430.
2. Bradshaw, T. D.; Stevens, M. F. G.; Westwell, A. D. The discovery of the potent and
selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and
related compounds. Curr. Med. Chem. 2001, 8, 203.
3. Kashiyama, E.; Hutchinson, I.; Chua, M-S.; Stinson, S. F.; Phillips, L. R.; Kaur, G.;
Sausville, E. A.; Bradshaw, T. D.; Westwell, A. D.; Stevens, M. F. G. Antitumor ben-
zothiazoles, 8: Synthesis, metabolic formation, and biological properties of the C- and
N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles. J. Med. Chem.
1999, 42, 4172.
4. Hutchinson, I.; Chua, M.-S.; Browne, H.; Trapani, V.; Fichtner, I.; Bradshaw, T. D.;
Westwell, A. D.; Stevens, M. F. G. Antitumor benzothiazoles, 14: Synthesis and in vitro
biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J. Med. Chem.
2001, 44, 1446.
5. Chua, M-S.; Kashiyama, E.; Bradshaw, T. D.; Stinson, S. F.; Brantley, E.; Sausville, E.
A.; Stevens, M. F. G. Role of CYP1A1 in modulation of antitumor properties of the novel
agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast
cancer cells. Cancer Res. 2000, 60, 5196.
6. Hutchinson, I.; Bradshaw, T. D.; Matthews, C. S.; Stevens, M. F. G.; Westwell, A. D.
Antitumour benzothiazoles, part 20: 30-Cyano and 30-alkynyl-substituted 2-(40-amino
phenyl)benzothiazoles as new potent and selective analogues. Bioorg. Med. Chem. Lett.
2003, 13, 471.
7. Bradshaw, T. D.; Westwell, A. D. The development of the antitumour benzothiazole
prodrug, Phortress, as a clinical candidate. Curr. Med. Chem. 2004, 11, 1009.
8. Hutchinson, I.; Jennings, S. A.; Vishnuvajjala, B. R.; Westwell, A. D.; Stevens, M. F. G.
Antitumor benzothiazoles, 16: Synthesis and pharmaceutical properties of antitumor
2-(4-aminophenyl)benzothiazole amino acid prodrugs. J. Med. Chem. 2002, 45, 744.
9. Westwell, A. D. The therapeutic potential of aryl hydrocarbon receptor (AhR) agonists in
anticancer drug development. Drugs Future 2004, 29, 479.
10. Mortimer, C. G.; Wells, G.; Crochard, J.-P.; Stone, E. L.; Bradshaw, T. D.; Stevens, M. F.
G.; Westwell, A. D. Antitumor benzothiazoles, 26: 2-(3,4-Dimethoxyphenyl)-5-fluoroben-
zothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent
and selective inhibitory activity against lung, colon, and breast cancer cell lines. J. Med.
Chem. 2006, 49, 179.
11. Henriksen, G.; Hauser, A. I.; Westwell, A. D.; Yousefi, B. H.; Schwaiger, M.; Drzezga, A.;
Wester, H.-J. Metabolically stabilized benzothiazoles for imaging of amyloid plaques.
J. Med. Chem. 2007, 50, 1087.
12. Mathis, C. A.; Wang, Y.; Holt, D. P.; Huang, G-F.; Debnath, M. L.; Klunk, W. E.
Synthesis and evaluation of C-11-labeled 6-substituted 2-arylbenzothiazoles as amyloid
imaging agents. J. Med. Chem. 2003, 46, 2740.
13. Weekes, A. A.; Dix, M. C.; Bagley, M. C.; Westwell, A. D. Rapid and convenient thermal
or microwave-assisted synthesis of substituted 2-phenylbenzothiazoles. Synth. Comm.
2010, 40, 3027.
14. Weekes, A. A.; Bagley, M. C.; Westwell, A. D. An efficient synthetic route to biologically
relevant 2-phenylbenzothiazoles substituted on the benzothiazole ring. Tetrahedron 2011,
67, 7743.
15. Hutchinson, I.; Stevens, M. F. G.; Westwell, A. D. The regiospecific synthesis of 5- and
7-monosubstituted and 5,6-disubstituted 2-arylbenzothiazoles. Tetrahedron Lett. 2000,
41, 425.